Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-19T22:41:03.608Z Has data issue: false hasContentIssue false
  • English
  • Français

Antibody capture radioimmunoassay (MACRIA) for coxsackievirus B4 and B5-specific IgM

Published online by Cambridge University Press:  15 May 2009

P. Morgan-Capner  and
C. McSorley
P. Morgan-Capner
Affiliation:
Department of Medical Microbiology, King's College Hospital Medical School, Denmark Hill, London 5E5 8RX
C. McSorley
Affiliation:
Department of Medical Microbiology, King's College Hospital Medical School, Denmark Hill, London 5E5 8RX
Rights & Permissions [Opens in a new window]

Summary

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

An antibody capture radioimmunoassay was established for the detection of coxsackievirus B4 and B5-specific IgM. A significant feature of the assay was the use of an unrefined coxsackievirus B (CBV) antigen. The antigen was prepared by freeze thawing, ultrasonication and low speed centrifugation of infected Vero cells with no purification or concentration of the antigen being performed. Results of sera tested were expressed as a serum ratio (SR) by comparison with a low positive control serum. To establish an SR indicating positivity in the assays, 100 antenatal sera collected in late February were tested. The mean SR was calculated and the mean plus three standard deviations was taken as the minimum SR indicating positivity. Although resulting in a relatively insensitive assay, such a value was required to exclude sera giving a low level of reactivity which may be due to residual enterovirus-specific IgM resulting from a remote infection.

The homologous CBV-IgM assay was positive in four cases of CBV4 infection and six cases of CBV5 infection. For the CBV4 IgM assay, ten of 20 (50%) sera from infections with CBV other than CBV4 were positive and nine of the 13(69%) sera from infections with echoviruses or coxsackieviruses A were positive. Five of 18 (27%) sera with an elevated CBV neutralization titre were positive in the CBV4-IgM assay. For the CB5-IgM assay seven of 18(39%) sera from infections with CBV other than CBV5 were positive and nine of 13 (69%) sera from infections with echoviruses or coxsackieviruses A were positive. The nine sera that were positive from this group in the CBV5-IgM assay were the same nine as were positive in the CBV4-IgM assay. Two of the 18(11%) sera with an elevated CBV neutralization titre were positive in the CBV5-IgM assay. These two sera were also positive in the CBV4-IgM assay and had an elevated monotypic CBV4 neutralization titre. None of the sera giving positive results gave significant reactivity when tested with control antigen. Twelve rheumatoid factor containing sera and 46 sera from other infections were negative in both assays. Of 24 sera from confirmed CBV infection, seven gave a positive monotypic CBV4 or 5-IgM response, ten were positive in both assays and seven were negative in both assays. The positive results seen with sera from cases of heterologous enterovirus infection may result from an anamnestic IgM response or, more likely, IgM directed against enterovirus cross-reacting antigens. The absence of homologous neutralizing antibody at a dilution of 1:20 in nine of 20 sera that gave a positive CBV-IgM result and the presence of positive results for CBV4 and 5-IgM in a 14 month old infant who had echovirus 7 infection indicates that the IgM need not be directed against neutralizing antigens.

Thus the CBV4 and 5-IgM assays developed appeared to be specific for an enterovirus infection but because of the cross-reactivity were not type-specific or group-specific.

Type
Research Article
Information
Journal of Hygiene , Volume 90 , Issue 3 , June 1983 , pp. 333 - 349
Copyright
Copyright © Cambridge University Press 1983

References

REFERENCES

Dorries, R. & Ter Meulen, V. (1980). Detection of enterovirus specific IgG and IgM antibodies in humans by an indirect solid phase radioimmunoassay. Medical Microbiology and Immunology 168, 159–171.CrossRefGoogle ScholarPubMed
El-Hagrassy, M. M. O., Banatvala, J. E. & Coltart, D. J. (1980). Coxsackie-B-virus-specific IgM responses in patients with cardiac and other diseases. Lancet ii, 1160–1162.CrossRefGoogle Scholar
Flehmig, B., Ranke, M., Berthold, H. & Gerth, J.-J. (1979). A solid phase radioimmunaossay for detection of IgM antibodies to hepatitis A virus. Journal of Infectious Diseases 140, 169–175.CrossRefGoogle ScholarPubMed
Grist, N. R. & Bell, , Eleanor, J. (1974). A six-year study of coxsackievirus B infections in heart disease. Journal of Hygiene, 73, 165–172.CrossRefGoogle ScholarPubMed
Grist, N. R., Bell, , Eleanor, J. & Assaad, Fakery (1978). Enteroviruses in Human Disease. Progress in Medical Virology 24, 114–157.Google ScholarPubMed
Katze, M. G. & Crowell, R. L. (1980 a). Indirect enzyme-linked immunosorbent assay (ELISA) for the detection of coxsackievirus Group B antibodies. Journal of General Virology 48, 225–229.CrossRefGoogle ScholarPubMed
Katze, M. G. & Crowell, R. L. (1980 b). Immunological studies of the group B coxsackieviruses by the sandwich enzyme-linked immunosorbent assay (ELISA) and immunoprecipitation. Journal of General Virology 50, 357–367.CrossRefGoogle Scholar
MacWilliam, K. M. & Cooper, M. A. (1974). Antibody levels in human sera measured by the flourescent-antibody technique against the coxsackie B viruses type 1–5 grown in HEp 2 cells compared with results obtained by neutralization. Journal of Clinical Pathology 27, 825–827.CrossRefGoogle Scholar
Melnick, J. L. (1982). Taxonomy and nomenclature of viruses, 1982. Progress in Medical Virology 28, 208–221.Google ScholarPubMed
Minor, T. E., Helstron, P. B., Nelson, D. B. & D'Alessio, D. J. (1979). Counterimmuno-electrophoresis test for immunoglobulin M antibodies to group B coxsackievirus. Journal of Clinical Microbiology 9, 503–506.CrossRefGoogle Scholar
Moroan-Capner, P., Tedder, R. S. & Mace, J. E. (1983). Rubella-specific IgM reactivity in sera from cases of infectious mononucleosis. Journal of Hygiene 90, 407–413.CrossRefGoogle Scholar
Mortimer, P. P., Tedder, R. S., Hambling, M. H., Shafi, M. S., Burkhardt, F. & Schilt, U. (1981). Antibody capture radioimmunoassay for anti-rubella IgM. Journal of Hygiene 86, 139–153.CrossRefGoogle ScholarPubMed
Salacinski, P., Hope, J., McLean, C., Clement-Jones, V., Sykes, J., Price, J. & Lowry, P. J. (1979). A new simple method which allows theoretical incorporation of radioiodine into proteins and peptides without damage. Journal of Endocrinology 81, 131–137.Google ScholarPubMed
Schmidt, N. J., Lennette, E. H. & Dennis, J. (1968). Characterization of antibodies produced in natural and experimental coxsackievirus infections. Journal of Immunology 100, 99–106.CrossRefGoogle ScholarPubMed
Schmidt, N. J., Magoffin, H. L. & Lennette, E. H. (1973). Association of group B coxsackieviruses with cases of pericarditis, myocarditis or pleurodynia by demonstration of immuno-globulin M antibody. Infection & Immunity 8, 341–348.CrossRefGoogle Scholar
Sexton, S. A., Hodoson, J. & Morgan-Capner, P. (1982). The detection of rubella-specific IgM by an immunosorbent assay with solid-phase attachment of red cells (SPARC). Journal of Hygiene 88, 453–461.CrossRefGoogle ScholarPubMed
Teare, E. L. (1982). Thesis for Master of Science in Medical Microbiology, University of London.Google Scholar
Tedder, R. S. (1981). Laboratory Investigation of Rubella. No. 16 PHLS Monograph Series (ed J. R., Pattison). London: H.M.S.O.Google Scholar
Tedder, R. S., Yao, J. L. & Anderson, M. J. (1982). The production of monoclonal antibodies to rubella haemagglutinins and their use in antibody-capture assays for rubella-specific IgM. Journal of Hygiene 88, 335–350.CrossRefGoogle ScholarPubMed